Caris Life Sciences (CAI) Other Non-Current Liabilities (2024 - 2026)
Caris Life Sciences (CAI) posted quarterly Other Non-Current Liabilities of $43.6 million for Q1 2026, up 2.86% quarter-over-quarter from $42.4 million in Q4 2025.
Caris Life Sciences (CAI) Other Non-Current Liabilities (2024 - 2026) Analysis & Trends
Caris Life Sciences' Other Non-Current Liabilities history runs 3 years deep, the most recent figure standing at $43.6 million for Q1 2026.
- In Q1 2026, Other Non-Current Liabilities changed N/A year-over-year to $43.6 million; the TTM figure through Mar 2026 stood at $43.6 million (changed N/A YoY), while the FY2025 annual figure was $42.4 million, down 53.75% from the prior year.
- Other Non-Current Liabilities for Q1 2026 stood at $43.6 million, up from $42.4 million in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $91.6 million in Q4 2024, with the low at $42.4 million in Q4 2025.
- The 3-year median for Other Non-Current Liabilities is $43.6 million (2026), against an average of $59.2 million.
- Peak annual rise in Other Non-Current Liabilities reached 53.75% in 2025, while the deepest fall reached 53.75% in 2025.
- Caris Life Sciences' Other Non-Current Liabilities stood at $91.6 million in 2024, then slumped by 53.75% to $42.4 million in 2025, then advanced by 2.86% to $43.6 million in 2026.
- Business Quant data shows CAI's Other Non-Current Liabilities at $43.6 million in Q1 2026, $42.4 million in Q4 2025, and $91.6 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Caris Life Sciences | 6.16 Bn | 5.37 Bn | 182.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 53.48 Mn |
| Mar 31, 2026 | 43.60 Mn |
| Dec 31, 2025 | 42.39 Mn |
| Dec 31, 2024 | 91.64 Mn |